NCT00072267View on ClinicalTrials.gov

UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2004

Primary Completion Date

April 30, 2005

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

7-hydroxystaurosporine

DRUG

topotecan hydrochloride

Trial Locations (4)

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

K1H 8L6

Ottawa Regional Cancer Centre, Ottawa

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University Health Network, Toronto

OTHER

NCT00072267 - UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Biotech Hunter | Biotech Hunter